Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: National Cancer Center, Zhejiang Cancer Hospital, Samsung Medical Center, Sungkyunkwan University, Chongqing University, Chongqing Cancer Hospital, Peking University Cancer Hospital, BeiGene (China), Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Chinese PLA General Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281674719